The Latest Breaking News from FDA

Blue-chip dividend stocks are of well-established companies offering steady income and financial stability. They are ideal for securing a resilient retirement portfolio, combining consistent dividends with potential capital appreciation. Thus, quality blue-chip dividend stocks Johnson & Johnson (JNJ), Coca-Cola (KO), and McDonald’s (MCD) could be ideal portfolio additions for retirement…

The FDA, which approved the protocols for the studies it now questions, is asking for an additional Phase 3 clinical trial, which would take years and millions of dollars.

Ascendis Pharma stock zoomed higher Monday — closing in on a breakout — after the FDA signed off on its embattled hypoparathyroid disease drug.

The Food and Drug Administration declined to approve MDMA as the first psychedelic drug used to treat post-traumatic stress disorder.

The new treatment, a needle-free alternative, could be used for managing severe allergic responses in children and adults, weighing at least 66 pounds, the FDA said.

JD Vance supports state autonomy in abortion policy, advocating for varied regulations based on state decisions.

FDA approves Neffy, a needle-free nasal spray epinephrine for anaphylaxis treatment, providing a convenient and effective option for severe allergic reactions.

FDA declines approval for MDMA as PTSD treatment, citing safety and efficacy concerns. Further trials needed.

Federal health officials have declined to approve the psychedelic drug MDMA as a therapy for PTSD

From infusion pumps to nebulizers, home medical equipment comes with potential problems for users.

FDA approves Jemperli for endometrial cancer, revolutionizing treatment options with immunotherapy. Keytruda and Imfinzi expand personalized therapies.